Mhd Rajeh, MD
Hematology & Oncology · Saint Louis, MONPI 1528452240
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by AbbVie at 45.5% of the total. Reporting peaked in 2023 at $2,849 and has fallen 94.0% since, to $170 in 2025.
Across 46 payments — averaging $120.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Astellas Pharma US Inc$582
- GSK$430
- Johnson & Johnson$397
- Amgen$294
- Gilead$279
- plus $1K from 14 others
Across 53 payments — averaging $6210.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$177K
- AbbVie$66K
- Pfizer$35K
- Epizyme, Inc.$30K
- Incyte Corporation$21K
What the payments were for
- Consulting fees$2,79350%
- Speaking & faculty fees$1503%
- Travel & lodging$200%
- Food & beverage$1,34124%
- Education$1,24622%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 4 | $2,527 |
| Astellas Pharma US Inc | 6 | $582 |
| GSK | 1 | $430 |
| Johnson & Johnson | 4 | $397 |
| Amgen | 5 | $294 |
| Gilead | 4 | $279 |
| Incyte Corporation | 3 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $159 |
| AstraZeneca | 1 | $150 |
| Agios Pharmaceuticals, Inc. | 1 | $129 |
| Genentech USA, Inc. | 1 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $96 |
| Taiho Oncology, Inc. | 1 | $40 |
| Merck | 2 | $30 |
| Novartis | 1 | $23 |
| Bristol Myers Squibb | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $19 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Janssen Scientific Affairs, LLC | 1 | $12 |
| Pfizer | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,549 in reported general payments places this provider in the 70th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 69 | $1,132,093 |
| PomalystPomalidomide | 26 | $504,448 |
| CalquenceAcalabrutinib Maleate | 24 | $401,062 |
| Lenalidomide | 19 | $345,357 |
| NinlaroIxazomib Citrate | 26 | $327,130 |
| IclusigPonatinib Hcl | 13 | $282,084 |
| JakafiRuxolitinib Phosphate | 13 | $259,856 |
| XareltoRivaroxaban | 16 | $10,184 |
| ValacyclovirValacyclovir Hcl | 28 | $1,823 |
| Dexamethasone | 29 | $683 |
| Acyclovir | 68 | $540 |
| Estazolam | 11 | $264 |
| Prochlorperazine Maleate | 24 | $259 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 43 | $157 |
| Ondansetron Hcl | 22 | $144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $22 | $1,132,09369 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro, Iclusig | $159 | $609,21439 claims |
| AstraZenecaCalquence | $150 | $401,06224 claims |
| Incyte CorporationJakafi | $238 | $259,85613 claims |
| Johnson & JohnsonXarelto | $397 | $10,18416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Saint Louis
- Mark FeslerSaint Louis$870K
- Jonathan MizrahiSaint Louis$188K
- Geoffrey UySaint Louis$28K
- Deepthi BusayavalasaSaint Louis$22K
- Jason LiSaint Louis$17K
- John FinnieSaint Louis$14K
- Atif ShafqatSaint Louis$7K
- Shabbir SafdarSaint Louis$7K
- Bryan FallerSaint Louis$6K
- Heide RodgersSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.